Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072579 · ClinicalTrials.gov registry record · Phase 2
Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00072579: Completed Phase 2 study, sponsored by Wake Forest University Health Sciences.
NCT00072579 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072579, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may bring about complete remission in patients who have chronic phase chronic myelogenous leukemia. PURPOSE: This phase II trial is studying sargramostim to see how well it works in treating patients with chronic phase chronic myelogenous leukemia that is not in complete cytogenetic remission after initial treatment.
Interventions
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-05 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00072579 record still lists
NCT00072579 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which sargramostim is the first listed.
NCT00072579 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00072579 about?
NCT00072579 is a clinical study titled "Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment". RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may bring about complete remission in patients who have chronic phase chronic myelogenous leukemia. PURPOSE: This phase II trial is studying sargramostim...
What is the current status of trial NCT00072579?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-05. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00072579?
The interventions under investigation include: sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072579?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia